Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Hypertension ; 75(3): 877-884, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31884859

RESUMO

Increasing evidence suggests a role for the ET (endothelin) system in preeclampsia. Hence, blocking this system with endothelin receptor antagonists (ERAs) could be a therapeutic strategy. Yet, clinical studies are lacking due to possible teratogenic effects of ERAs. In this study, we investigated the placental transfer of ERAs and their effect on ET-1-mediated vasoconstriction. Term placentas were dually perfused with the selective ETAR (ET type A receptor) antagonists sitaxentan and ambrisentan or the nonselective ETAR/ETBR antagonist macitentan and subsequently exposed to ET-1 in the fetal circulation. ET-1 concentration-response curves after incubation with sitaxentan, ambrisentan, macitentan, or the selective ETBR antagonist BQ-788 were also constructed in isolated chorionic plate arteries using wire-myography, and gene expression of the ET-system was quantified in healthy and early onset preeclamptic placentas. At steady state, the mean fetal-to-maternal transfer ratios were 0.32±0.05 for sitaxentan, 0.21±0.02 for ambrisentan, and 0.05±0.01 for macitentan. Except for BQ-788, all ERAs lowered the response to ET-1, both in the perfused cotyledon and isolated chorionic plate arteries. Placental gene expression of ECE-1, ETAR, and ETBR were comparable in healthy and preeclamptic placentas, while ET-1 expression was higher in preeclampsia. Our study is the first to show direct transfer of ERAs across the term human placenta. Furthermore, ETAR exclusively mediates ET-1-induced constriction in the fetoplacental vasculature. Given its limited transfer, macitentan could be considered as potential preeclampsia therapy. Extending knowledge on placental transfer to placentas of preeclamptic pregnancies is required to determine whether ERAs might be applied safely in preeclampsia.


Assuntos
Antagonistas dos Receptores de Endotelina/farmacologia , Placenta/efeitos dos fármacos , Vasoconstrição/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Endotelina-1/biossíntese , Endotelina-1/sangue , Endotelina-1/genética , Enzimas Conversoras de Endotelina/biossíntese , Enzimas Conversoras de Endotelina/genética , Feminino , Transfusão Feto-Materna , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Isoxazóis/farmacologia , Oligopeptídeos/farmacologia , Fenilpropionatos/farmacologia , Piperidinas/farmacologia , Placenta/irrigação sanguínea , Placenta/metabolismo , Pré-Eclâmpsia/tratamento farmacológico , Gravidez , Piridazinas/farmacologia , Pirimidinas/farmacologia , Receptor de Endotelina A/biossíntese , Receptor de Endotelina A/efeitos dos fármacos , Receptor de Endotelina A/genética , Receptor de Endotelina A/fisiologia , Receptor de Endotelina B/biossíntese , Receptor de Endotelina B/genética , Sulfonamidas/farmacologia , Tiofenos/farmacologia
2.
SLAS Technol ; 23(3): 207-216, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29412765

RESUMO

Nomad Technology (Innoprot [Innovative Technologies in Biological Systems], Derio, Spain), a novel tool for multiplexing high-throughput cell-based G protein-coupled receptor (GPCR) assays, is described in this work. This new technology comprises a family of fluorescent biosensors called Nomad Biosensors that allow for the measurement of responses mediated by G proteins through their interactions with second-messenger transduction proteins. GPCRs are one of the largest protein families of receptors in eukaryotes, and their signaling mediates important physiological processes within cells. Thus, GPCRs are associated with a wide variety of diseases, and considered major targets in therapeutic research. Nomad constitutes a novel tool for unraveling the mechanism of GPCR signal transduction by simultaneously tracing different pathways. GPCR activation changes the structural folding of the biosensor and promotes its vesicularization, as well as an increase in the fluorescence intensity. Based on this technology, the MPXNomad cellular model was developed to discriminate between the Ca2+-mediated pathway and the cyclic adenosine monophosphate (cAMP)-mediated pathway. To validate this model, endothelin receptor B (ETBR) was coexpressed into the MPXNomad cell line and assessed with a specific agonist, an antagonist, and a chemical library of compounds. Nomad Technology optimizes the identification of novel GPCR ligands and enables the testing of large numbers of compounds.


Assuntos
Técnicas Biossensoriais , Avaliação Pré-Clínica de Medicamentos/métodos , Ensaios de Triagem em Larga Escala/métodos , Cálcio/metabolismo , Linhagem Celular Tumoral , Clonagem Molecular , AMP Cíclico/metabolismo , Endotelinas/metabolismo , Fluorescência , Humanos , Processamento de Imagem Assistida por Computador , Ligantes , Receptor de Endotelina B/genética , Receptor de Endotelina B/metabolismo , Receptores Acoplados a Proteínas G/agonistas , Transdução de Sinais
3.
J Physiol Biochem ; 72(4): 763-779, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27534650

RESUMO

Decline in oxygen availability experienced under hypobaric hypoxia (HH) mediates imbalance in lung fluid clearance and is a causative agent of acute lung injury. Here, we investigate the pathological events behind acute HH mediated lung injury and assess the therapeutic efficacy of nanocurcumin in its amelioration. We assess the protective efficacy of nanotized curcumin (nanocurcumin) in ameliorating HH induced lung injury and compare to curcumin. Rats exposed to acute HH (6, 12, 24, 48 and 72 h) were subjected to histopathology, blood-gas analysis and clinical biochemistry, cytokine response and redox damage. HH induced lung injury was analysed using markers of lung injury due to pulmonary vasoconstriction (ET-1/2/3 and endothelin receptors A and B) and trans-vascular fluid balance mediator (Na+/K+ ATPase). The protective efficacy of nanocurcumin was analysed by examination of Akt/Erk signalling cascade by western blot. HH induced lung injury was associated with discrete changes in blood analytes, differential circulatory cytokine response and severe pulmonary redox damages. Up-regulation of ET-1/2/3 and its receptors along with down-regulation of Na+/K+ ATPase confirmed defective pulmonary fluid clearance which promoted edema formation. Nanocurcumin treatment prevented lung edema formation and restored expression levels of ET-1/2/3 and its receptors while restoring the blood analytes, circulatory cytokines and pulmonary redox status better than curcumin. Modulation in Akt/Erk signalling pathway in rat lungs under HH confirmed the protective efficacy of nanocurcumin.


Assuntos
Lesão Pulmonar Aguda/tratamento farmacológico , Curcumina/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Hipóxia/tratamento farmacológico , Nanoestruturas/uso terapêutico , Substâncias Protetoras/farmacologia , Lesão Pulmonar Aguda/etiologia , Lesão Pulmonar Aguda/genética , Lesão Pulmonar Aguda/patologia , Animais , Biomarcadores/metabolismo , Modelos Animais de Doenças , Endotelina-1/genética , Endotelina-1/metabolismo , Endotelina-2/genética , Endotelina-2/metabolismo , Endotelina-3/genética , Endotelina-3/metabolismo , Hipóxia/complicações , Hipóxia/genética , Hipóxia/patologia , Masculino , Proteína Quinase 1 Ativada por Mitógeno/genética , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno/genética , Proteína Quinase 3 Ativada por Mitógeno/metabolismo , Nanoestruturas/química , Oxirredução/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-akt/genética , Proteínas Proto-Oncogênicas c-akt/metabolismo , Ratos , Ratos Sprague-Dawley , Receptor de Endotelina A/genética , Receptor de Endotelina A/metabolismo , Receptor de Endotelina B/genética , Receptor de Endotelina B/metabolismo , Transdução de Sinais , ATPase Trocadora de Sódio-Potássio/genética , ATPase Trocadora de Sódio-Potássio/metabolismo
4.
PLoS One ; 10(6): e0128678, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26030901

RESUMO

Melanogenesis is the physiological process by which melanin is synthesized to protect the skin from UV damage. While paracrine interactions between keratinocytes and melanocytes are crucial for regulating epidermal pigmentation, the endothelin (EDN)-endothelin B-receptor (EDNRB) interaction is one of the key linkages. In this study, we found that a single exposure of normal human melanocytes (NHMs) with UVB stimulates the expression of EDNRB and its upstream transcription factor microphthalmia-associated transcription factor (MITF) at the transcriptional and translational levels. That stimulation can be abrogated by post-irradiation treatment with a French maritime pine bark extract (PBE). UVB stimulated the phosphorylation of p38 and c-jun N-terminal kinase (JNK), but not ERK, followed by the increased phosphorylation of MSK1 and CREB. The post-irradiation treatment with PBE did not affect the increased phosphorylation of p38 and JNK, but distinctly abrogated the phosphorylation of MSK1 and CREB. Post-irradiation treatment with the MSK1 inhibitor H89 significantly down-regulated the increased gene expression of MITF and EDNRB in UVB-exposed NHMs. Our findings indicate for the first time that the increased expression of MITF that leads to the up-regulation of melanocyte-specific proteins in UVB-exposed NHMs is mediated via activation of the p38/MSK1/CREB pathway but not the ERK/RSK/CREB pathway. The mode of action by PBE demonstrates that interrupting MSK1 activation is a new target for antioxidants including PBE which can serve as anti-pigmenting agents in a reactive oxygen species-depletion-independent manner.


Assuntos
Melanócitos/efeitos dos fármacos , Pinus/química , Extratos Vegetais/farmacologia , Receptor de Endotelina B/genética , Proteínas Quinases S6 Ribossômicas 90-kDa/genética , Transdução de Sinais/efeitos dos fármacos , Raios Ultravioleta/efeitos adversos , Células Cultivadas , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/genética , Endotelinas/efeitos dos fármacos , Endotelinas/genética , Expressão Gênica/efeitos dos fármacos , Expressão Gênica/genética , Humanos , Proteínas Quinases JNK Ativadas por Mitógeno/genética , Queratinócitos/efeitos dos fármacos , Melaninas/genética , Melanócitos/metabolismo , Fator de Transcrição Associado à Microftalmia/genética , Fosforilação/efeitos dos fármacos , Fosforilação/genética , Pigmentação/efeitos dos fármacos , Pigmentação/genética , Casca de Planta/química , Transdução de Sinais/genética , Pele/efeitos dos fármacos , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/genética , Proteínas Quinases p38 Ativadas por Mitógeno/genética
5.
PLoS One ; 9(3): e92417, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24642693

RESUMO

BACKGROUND: Global cerebral ischemia following cardiac arrest is associated with increased cerebral vasoconstriction and decreased cerebral blood flow, contributing to delayed neuronal cell death and neurological detriments in affected patients. We hypothesize that upregulation of contractile ETB and 5-HT1B receptors, previously demonstrated in cerebral arteries after experimental global ischemia, are a key mechanism behind insufficient perfusion of the post-ischemic brain, proposing blockade of this receptor upregulation as a novel target for prevention of cerebral hypoperfusion and delayed neuronal cell death after global cerebral ischemia. The aim was to characterize the time-course of receptor upregulation and associated neuronal damage after global ischemia and investigate whether treatment with the MEK1/2 inhibitor U0126 can prevent cerebrovascular receptor upregulation and thereby improve functional outcome after global cerebral ischemia. Incomplete global cerebral ischemia was induced in Wistar rats and the time-course of enhanced contractile responses and the effect of U0126 in cerebral arteries were studied by wire myography and the neuronal cell death by TUNEL. The expression of ETB and 5-HT1B receptors was determined by immunofluorescence. RESULTS: Enhanced vasoconstriction peaked in fore- and midbrain arteries 3 days after ischemia. Neuronal cell death appeared initially in the hippocampus 3 days after ischemia and gradually increased until 7 days post-ischemia. Treatment with U0126 normalised cerebrovascular ETB and 5-HT1B receptor expression and contractile function, reduced hippocampal cell death and improved survival rate compared to vehicle treated animals. CONCLUSIONS: Excessive cerebrovascular expression of contractile ETB and 5-HT1B receptors is a delayed response to global cerebral ischemia peaking 3 days after the insult, which likely contributes to the development of delayed neuronal damage. The enhanced cerebrovascular contractility can be prevented by treatment with the MEK1/2 inhibitor U0126, diminishes neuronal damage and improves survival rate, suggesting MEK1/2 inhibition as a novel strategy for early treatment of neurological consequences following global cerebral ischemia.


Assuntos
Isquemia Encefálica/tratamento farmacológico , Butadienos/farmacologia , Hipóxia Encefálica/prevenção & controle , Nitrilas/farmacologia , Receptor de Endotelina B/metabolismo , Receptor 5-HT1B de Serotonina/metabolismo , Animais , Isquemia Encefálica/patologia , Butadienos/uso terapêutico , Circulação Cerebrovascular/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , MAP Quinase Quinase 1/antagonistas & inibidores , MAP Quinase Quinase 1/metabolismo , MAP Quinase Quinase 2/antagonistas & inibidores , MAP Quinase Quinase 2/metabolismo , Nitrilas/uso terapêutico , Ratos , Ratos Wistar , Receptor de Endotelina B/genética , Receptor 5-HT1B de Serotonina/genética , Resultado do Tratamento , Regulação para Cima/efeitos dos fármacos , Vasoconstrição/efeitos dos fármacos
6.
Neurogastroenterol Motil ; 25(3): e233-44, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23360229

RESUMO

BACKGROUND: Hirschsprung's disease (HSCR) is a congenital condition in which enteric ganglia, formed from neural crest cells (NCC), are absent from the terminal bowel. Dysmotility and constipation are common features of HSCR that persist following surgical intervention. This persistence suggests that the portion of the colon that remains postoperatively is not able to support normal bowel function. To elucidate the defects that underlie this condition, we utilized a murine model of HSCR. METHODS: Mice with NCC-specific deletion of Ednrb were used to measure the neuronal density and neurotransmitter expression in ganglia. KEY RESULTS: At the site located proximal to the aganglionic region of P21 Ednrb null mice, the neuronal density is significantly decreased and the expression of neurotransmitters is altered compared with het animals. The ganglia in this colonic region are smaller and more isolated while the size of neuronal cell bodies is increased. The percentage of neurons expressing neuronal nNOS and VIP is significantly increased in Ednrb nulls. Conversely, the percentage of choline acetyltransferase (ChAT) expressing neurons is decreased, while Substance P is unchanged between the two genotypes. These changes are limited to the colon and are not detected in the ileum. CONCLUSIONS & INFERENCES: We demonstrate changes in neuronal density and alterations in the balance of expression of neurotransmitters in the colon proximal to the aganglionic region in Ednrb null mice. The reduced neuronal density and complementary changes in nNOS and ChAT expression may account for the dysmotility seen in HSCR.


Assuntos
Colo/patologia , Sistema Nervoso Entérico/patologia , Doença de Hirschsprung/patologia , Neurônios/patologia , Neurotransmissores/biossíntese , Animais , Colo/inervação , Modelos Animais de Doenças , Sistema Nervoso Entérico/metabolismo , Doença de Hirschsprung/genética , Doença de Hirschsprung/metabolismo , Imuno-Histoquímica , Camundongos , Camundongos Knockout , Receptor de Endotelina B/deficiência , Receptor de Endotelina B/genética
7.
Biol Trace Elem Res ; 150(1-3): 173-7, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23065423

RESUMO

The objective of this study was to evaluate the effects of supplemental selenium (Se) on expression of endothelin-1 (ET-1) and its receptors in cultured chick embryos pulmonary microvascular endothelial cells (PMVECs). To accomplish this, PMVECs were treated in Se-deficient or Se-supplement (12, 24, 50, 100 ng/ml) culture medium for 48 h. Low Se medium was achieved by reducing serum concentrations and the essential growth factors were added. After the incubation, the effects of supplemental Se on ET-1 and its receptors gene expression were assessed by quantitative real-time PCR (qRT-PCR). Compared with the control group, our results showed that among the different concentrations of Se supplement, the levels of ET-1 gene expression treated with both the moderate Se doses (24, 50 ng/ml, P < 0.01, P < 0.01, respectively) and the high doses (100 ng/ml, P < 0.05) were noticeably decreased, the low-dose group (12 ng/ml), which showed no changes. Meanwhile, Se supplement (24, 50, 100 ng/ml) was found to be effective in reducing the expression levels of ETA (P < 0.01, P < 0.05, P < 0.05, respectively) in cultured PMVECs grown in low Se medium. However, there were no significant changes (P > 0.05) in ETB mRNA levels during the cell proliferation. These observations indicated that Se may play both direct and indirect role in the regulation of ET-1 and its receptors gene expression and their production in avian PMVECs. Se supplement decreases in ET-1 and ETA production in Se-deficient PMVECs may partly explain the mechanism of the protective effects of the Se on the cardiovascular system.


Assuntos
Endotelina-1/metabolismo , Endotélio Vascular/metabolismo , Regulação da Expressão Gênica no Desenvolvimento , Pulmão/metabolismo , Microvasos/metabolismo , Receptor de Endotelina A/metabolismo , Selênio/metabolismo , Animais , Proteínas Aviárias/antagonistas & inibidores , Proteínas Aviárias/genética , Proteínas Aviárias/metabolismo , Doenças Cardiovasculares/prevenção & controle , Sobrevivência Celular , Células Cultivadas , Embrião de Galinha , Regulação para Baixo , Antagonistas do Receptor de Endotelina A , Endotelina-1/antagonistas & inibidores , Endotelina-1/genética , Endotélio Vascular/citologia , Endotélio Vascular/embriologia , Pulmão/citologia , Pulmão/embriologia , Microvasos/citologia , Microvasos/embriologia , Concentração Osmolar , Substâncias Protetoras/metabolismo , Substâncias Protetoras/uso terapêutico , RNA Mensageiro/metabolismo , Receptor de Endotelina A/genética , Receptor de Endotelina B/genética , Receptor de Endotelina B/metabolismo , Reprodutibilidade dos Testes , Selênio/deficiência , Selênio/uso terapêutico , Selenito de Sódio/metabolismo
8.
PLoS One ; 7(8): e43199, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22916224

RESUMO

Glaucoma is an optic neuropathy, commonly associated with elevated intraocular pressure (IOP) characterized by optic nerve degeneration, cupping of the optic disc, and loss of retinal ganglion cells which could lead to loss of vision. Endothelin-1 (ET-1) is a 21-amino acid vasoactive peptide that plays a key role in the pathogenesis of glaucoma; however, the receptors mediating these effects have not been defined. In the current study, endothelin B (ET(B)) receptor expression was assessed in vivo, in the Morrison's ocular hypertension model of glaucoma in rats. Elevation of IOP in Brown Norway rats produced increased expression of ET(B) receptors in the retina, mainly in retinal ganglion cells (RGCs), nerve fiber layer (NFL), and also in the inner plexiform layer (IPL) and inner nuclear layer (INL). To determine the role of ET(B) receptors in neurodegeneration, Wistar-Kyoto wild type (WT) and ET(B) receptor-deficient (KO) rats were subjected to retrograde labeling with Fluoro-Gold (FG), following which IOP was elevated in one eye while the contralateral eye served as control. IOP elevation for 4 weeks in WT rats caused an appreciable loss of RGCs, which was significantly attenuated in KO rats. In addition, degenerative changes in the optic nerve were greatly reduced in KO rats compared to those in WT rats. Taken together, elevated intraocular pressure mediated increase in ET(B) receptor expression and its activation may contribute to a decrease in RGC survival as seen in glaucoma. These findings raise the possibility of using endothelin receptor antagonists as neuroprotective agents for the treatment of glaucoma.


Assuntos
Glaucoma/metabolismo , Receptor de Endotelina B/metabolismo , Células Ganglionares da Retina/metabolismo , Animais , Modelos Animais de Doenças , Glaucoma/genética , Pressão Intraocular/genética , Pressão Intraocular/fisiologia , Masculino , Fibras Nervosas/metabolismo , Hipertensão Ocular/genética , Hipertensão Ocular/metabolismo , Ratos , Ratos Wistar , Receptor de Endotelina B/genética
9.
Mol Endocrinol ; 21(5): 1192-204, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17312275

RESUMO

Mammalian endothelin (ET) receptors, termed ET(A)R and ET(B)R, are derived from two intron-containing genes and the functional splice variants of ET(B)R but not ET(A)R have been identified. Here, we report about the isolation of cDNAs of ET(A)R transcripts from rat anterior pituitary, which are generated by alternative RNA splicing. Deletion of exon 2 and insertion of fragments from intron 1 and 2 accounted for formation of three misplaced proteins, whereas the insertion of a fragment from intron 6 resulted in generation of a functional plasma membrane receptor, termed ET(A)R-C13. In this splice variant, the C-terminal 382S-426N sequence of ET(A)R was substituted with a shorter 382A-399L sequence, resulting in alteration of the putative domains responsible for coupling to G(q/11) and G(s) proteins and the endocytotic recycling, as well as in deletion of the predicted protein kinase C/casein kinase 2 phosphorylation sites. The mRNA transcripts for ET(A)R-C13 were identified in normal and immortalized pituitary cells and several other tissues. The pharmacological profiles of recombinant ET(A)R and ET(A)R-C13 were highly comparable, but the coupling of ET(A)R-C13 to the calcium-mobilizing signaling pathway was attenuated, causing a rightward shift in the potency for agonist. Furthermore, the efficacy of ET(A)R-C13 to stimulate adenylyl cyclase signaling pathway and to internalize was significantly reduced. These results indicate for the first time the presence of a novel ET(A) splice receptor, which could contribute to the functional heterogeneity among secretory pituitary cell types.


Assuntos
Adeno-Hipófise/fisiologia , Receptor de Endotelina A/genética , Receptor de Endotelina B/genética , Processamento Alternativo , Sequência de Aminoácidos , Animais , Células CHO , Células Cultivadas , Clonagem Molecular , Cricetinae , Cricetulus , Primers do DNA , DNA Complementar/genética , Feminino , Variação Genética , Humanos , Dados de Sequência Molecular , Isoformas de Proteínas/genética , Ratos , Ratos Sprague-Dawley , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transcrição Gênica
10.
J Pharmacol Sci ; 94(3): 287-96, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15037814

RESUMO

The present study was conducted to evaluate the contribution of endothelin (ET) to the pharmacodynamic response to chronic cigarette smoke in spontaneously hypertensive rats (SHR). The contribution of ET was studied consequent to the hemodynamic response following 8 weeks of cigarette smoke by determining the changes in tissue ET-1 content and ET receptors. The blood pressure (BP) at the early phase of smoking and the heart rate (HR) 24 h later were apparently reduced in SHR, while the HR at the early phase was transiently elevated in normotensive Wistar Kyoto (WKY) rats. Tissue ET-1 levels in the hypothalamus, striatum, and cortex of SHR were higher than those in WKY rats, and these higher levels in SHR were reduced by exposure to chronic cigarette smoke. The ET-1 contents in the medulla oblongata and midbrain of both strains were clearly increased by smoke exposure, although the levels of SHR and WKY rats were not different. In addition, the immunoreactivity of the ET type A receptor in the adrenal glands and type B receptor in the kidneys of SHR showed a different response to smoke exposure as compared to WKY rats. Our present findings suggest that the changes of ETs may relate to the pharmacodynamic effects of chronic cigarette smoke.


Assuntos
Química Encefálica/fisiologia , Endotelinas/fisiologia , Nicotiana/efeitos adversos , Receptor de Endotelina A/metabolismo , Receptor de Endotelina B/metabolismo , Fumar/fisiopatologia , Medula Suprarrenal/efeitos dos fármacos , Medula Suprarrenal/fisiologia , Medula Suprarrenal/ultraestrutura , Animais , Pressão Sanguínea/efeitos dos fármacos , Química Encefálica/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos/métodos , Endotelinas/efeitos dos fármacos , Coração/efeitos dos fármacos , Coração/fisiologia , Frequência Cardíaca/efeitos dos fármacos , Rim/efeitos dos fármacos , Rim/fisiologia , Masculino , Ratos , Ratos Endogâmicos SHR , Ratos Endogâmicos WKY , Receptor de Endotelina A/efeitos dos fármacos , Receptor de Endotelina A/genética , Receptor de Endotelina B/efeitos dos fármacos , Receptor de Endotelina B/genética , Fumaça/efeitos adversos , Fumar/efeitos adversos , Fatores de Tempo
11.
Br J Pharmacol ; 139(4): 765-74, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12813000

RESUMO

1 Physiologically, perisinusoidal hepatic stellate cells (HSC) are quiescent and store retinoids. During liver injury and in cell culture, HSC transform into proliferating myofibroblast-like cells that express alpha-smooth muscle actin (alpha-sma) and produce excessive amounts of extracellular matrix. During transformation (also known as activation), HSC are depleted of the retinoid stores, and their expression of the endothelin-1 (ET-1) system is increased. ET-1 causes contraction of transformed HSC and is implicated in their proliferation and fibrogenic activity. In order to understand the association between retinoids, ET-1 and the activation of HSC, we investigated the effect of 13-cis-retinoic acid on the transformation of cultured HSC and the expression of ET-1 system. 2 HSC derived from normal rat liver were maintained for 10-12 days in a medium supplemented with 5% serum and containing 2.5 micro M retinoic acid without or with 50 nM ET-1 (ETA+ETB agonist) or sarafotoxin S6c (ETB agonist). In another set of experiments, cells treated for 10-12 days with vehicle (ethanol) or retinoic acid were challenged with ET-1 or sarafotoxin S6c, and various determinations were made at 24 h. 3 Retinoic acid inhibited transformation and proliferation of HSC as assessed by morphological characteristics, expression of alpha-sma, bromodeoxyuridine incorporation and cell count. Retinoic acid also prevented upregulation of ETB receptors without affecting ET-1 or ETA expression. Total protein synthesis ([(3)H]leucine incorporation), collagen alpha types I mRNA expression and collagen synthesis ([(3)H]proline incorporation) were lower in retinoic acid-treated cells. Although ET-1-treated cells were morphologically similar to the control cells, their expression of alpha-smooth muscle actin was significantly inhibited. The presence of retinoic acid in the medium during treatment with ET-1 caused further reduction in the expression of alpha-smooth muscle actin. ET-1 and sarafotoxin S6c stimulated total protein synthesis in vehicle- and retinoic acid-treated cells, but collagen synthesis only in the latter. 4 These results showing prevention of HSC activation and negative regulation of ETB receptor expression in them by retinoic acid may have important pathophysiologic implications.


Assuntos
Diferenciação Celular/efeitos dos fármacos , Antagonistas do Receptor de Endotelina B , Hepatócitos/efeitos dos fármacos , Receptor de Endotelina B/efeitos dos fármacos , Tretinoína/farmacologia , Regulação para Cima/efeitos dos fármacos , Animais , Divisão Celular , Células Cultivadas , Colágeno/biossíntese , Colágeno/genética , Citoplasma/ultraestrutura , Endotelina-1/efeitos dos fármacos , Endotelina-1/metabolismo , Matriz Extracelular/metabolismo , Proteínas da Matriz Extracelular/genética , Proteínas da Matriz Extracelular/metabolismo , Regulação Enzimológica da Expressão Gênica , Hepatócitos/metabolismo , Ratos , Receptor de Endotelina B/genética , Receptores de Endotelina , Fator de Crescimento Transformador beta/biossíntese , Fator de Crescimento Transformador beta/genética , Tretinoína/metabolismo , Regulação para Cima/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA